



# Corrigendum: Coronavirus Disease-2019 Survival in Mexico: A Cohort Study on the Interaction of the Associated Factors

Horacio Márquez-González<sup>1</sup>, Jorge F. Méndez-Galván<sup>2</sup>, Alfonso Reyes-López<sup>3</sup>, Miguel Klünder-Klünder<sup>4</sup>, Rodolfo Jiménez-Juárez<sup>5</sup>, Juan Garduño-Espinosa<sup>6</sup> and Fortino Solórzano-Santos<sup>7\*</sup>

<sup>1</sup> Department of Clinical Research, Hospital Infantil de México Federico Gómez, Mexico City, Mexico, <sup>2</sup> Centre for Research in Emerging Diseases, Hospital Infantil de México Federico Gómez, Mexico City, Mexico, <sup>3</sup> Centre for Health Economics, Hospital Infantil de México Federico Gómez, Mexico City, Mexico, <sup>4</sup> Research Management, Hospital Infantil de México Federico Gómez, Mexico City, Mexico, <sup>5</sup> Clinical Infectious Disease Department, Hospital Infantil de México Federico Gómez, Mexico City, Mexico, <sup>6</sup> Clinical Research Direction, Hospital Infantil de México Federico Gómez, Mexico City, Mexico, <sup>7</sup> Infectious Diseases Research Department, Hospital Infantil de México Federico Gómez, Mexico City, Mexico

**Keywords:** Mexico, SARS-CoV-2, survival analysis, cohort study, comorbidity, COVID-19 outbreak

## OPEN ACCESS

### Edited and reviewed by:

Burc Barin,  
Emmes Corporation, United States

### \*Correspondence:

Fortino Solórzano-Santos  
solorzanof056@gmail.com

### Specialty section:

This article was submitted to  
Infectious Diseases - Surveillance,  
Prevention and Treatment,  
a section of the journal  
Frontiers in Public Health

**Received:** 06 August 2021

**Accepted:** 12 August 2021

**Published:** 29 September 2021

### Citation:

Márquez-González H,  
Méndez-Galván JF, Reyes-López A,  
Klünder-Klünder M, Jiménez-Juárez R,  
Garduño-Espinosa J and  
Solórzano-Santos F (2021)  
Corrigendum: Coronavirus  
Disease-2019 Survival in Mexico: A  
Cohort Study on the Interaction of the  
Associated Factors.  
Front. Public Health 9:754703.  
doi: 10.3389/fpubh.2021.754703

## A Corrigendum on

### Coronavirus Disease-2019 Survival in Mexico: A Cohort Study on the Interaction of the Associated Factors

by Márquez-González, H., Méndez-Galván, J. F., Reyes-López, A., Klünder-Klünder, M., Jiménez-Juárez, R., Garduño-Espinosa, J., and Solórzano-Santos, F. (2021). *Front. Public Health* 9:660114. doi: 10.3389/fpubh.2021.660114

In the original article, there were some errors. “Comorbidities” was misspelled. All instances of the incorrect spelling should be corrected to read “comorbidities”.

The acronym for chronic obstructive pulmonary disease was incorrectly spelled. This should be COPD.

In the original articles, there were some mistakes in **Table 2**.

The section “Taquism” should be named “Smoking”. The row “Taquism” in the “Outcomes” section was deleted. “Immunossuppression” should read “Immunocompression”.

The corrected table appears below.

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Márquez-González, Méndez-Galván, Reyes-López, Klünder-Klünder, Jiménez-Juárez, Garduño-Espinosa and Solórzano-Santos. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

**TABLE 2** | Differences between survivors and non-survivors with SARS CoV-2.

Variables	Survival		No survival		p-value
	n	%	n	%	
<b>Sex</b>					
Male	340,076	50.40%	50,340	64.10%	<0.0001
Female	334,244	49.60%	28,152	35.90%	
<b>Group Age</b>					
<2 years	2,383	0.40%	121	0.20%	<0.0001
2.1–5.9	2,557	0.40%	33	0.00%	
6–9.9	4,255	0.60%	39	0.00%	
10–18.9	15,628	2.30%	102	0.10%	
19– <40	284,456	42.20%	4,337	5.50%	
40– <50	151,988	22.50%	9,252	11.80%	
50– <60	114,663	17.00%	17,446	22.20%	
60– <70	60,976	9.00%	21,766	27.70%	
70–79.9	26,723	4.00%	16,741	21.30%	
80+	10,691	1.60%	8,655	11.00%	
<b>Type</b>					
Ambulatory	564,547	83.70%	8,977	11.40%	<0.0001
Hospitalization	109,773	16.30%	69,515	88.60%	
<b>Comorbidities</b>					
Diabetes	85,614	12.70%	30,096	38.30%	<0.0001
COPD	7,085	1.10%	3,813	4.90%	<0.0001
Asthma	17,889	2.70%	1,578	2.00%	<0.0001
Immunocompression	6,159	0.90%	1,935	2.50%	<0.0001
Hypertension	109,956	16.30%	35,221	44.90%	<0.0001
Cardiovascular disease	10,572	1.60%	4,175	5.30%	<0.0001
Obesity	116,071	17.20%	19,182	24.40%	<0.0001
Renal chronic disease	8,635	1.30%	5,529	7.00%	<0.0001
Smoking	48,622	7.20%	6,264	8.00%	<0.0001
<b>Outcomes</b>					
Pneumonia	79,584	11.80%	58,078	74.00%	<0.0001
Invasive mechanical ventilation	5,898	0.90%	25,539	32.50%	<0.0001
Intensive care unit	7,514	1.10%	7,890	10.10%	<0.0001

The value of p was calculated by  $\chi^2$  test.